165 related articles for article (PubMed ID: 23065016)
1. Central serous chorioretinopathy due to tadalafil use.
Türkcü FM; Yüksel H; Şahin A; Murat M; Bozkurt Y; Çaça I
Int Ophthalmol; 2013 Apr; 33(2):177-80. PubMed ID: 23065016
[TBL] [Abstract][Full Text] [Related]
2. [Serous central chorioretinopathy and tadalafil: a case report].
Nadeau S; Nguyen F; Guigou S
J Fr Ophtalmol; 2012 Feb; 35(2):121.e1-5. PubMed ID: 21680058
[TBL] [Abstract][Full Text] [Related]
3. Central serous chorioretinopathy following oral tadalafil intake.
Roy R; Panigrahi PK; Saurabh K; Das D; Lobo A
Clin Exp Optom; 2014 Sep; 97(5):473-4. PubMed ID: 24612146
[No Abstract] [Full Text] [Related]
4. Central serous chorioretinopathy following oral tadalafil.
Gordon-Bennett P; Rimmer T
Eye (Lond); 2012 Jan; 26(1):168-9. PubMed ID: 22056864
[No Abstract] [Full Text] [Related]
5. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?
Aliferis K; Petropoulos IK; Farpour B; Matter MA; Safran AB
Ophthalmologica; 2012; 227(2):85-9. PubMed ID: 22156704
[TBL] [Abstract][Full Text] [Related]
6. [Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors].
Smal C; Lepièce G; Bonnet S
Rev Med Liege; 2017 Nov; 72(11):475-477. PubMed ID: 29171944
[TBL] [Abstract][Full Text] [Related]
7. Leber's hereditary optic neuropathy precipitated by tadalafil use for erectile dysfunction.
Cornish KS; Barras C
Semin Ophthalmol; 2011 Jan; 26(1):7-10. PubMed ID: 21275598
[TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography in tadalafil-associated retinal toxicity.
Coscas F; Coscas G; Zucchiatti I; Bandello F; Soubrane G; Souïed E
Eur J Ophthalmol; 2012; 22(5):853-6. PubMed ID: 22328305
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
Kamenov ZA
J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
[TBL] [Abstract][Full Text] [Related]
11. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Porst H; Hell-Momeni K; Büttner H
Expert Opin Pharmacother; 2012 Jul; 13(10):1481-94. PubMed ID: 22725705
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
14. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis.
Lombardi G; Macchiarella A; Del Popolo G
J Sex Med; 2010 Jun; 7(6):2192-2200. PubMed ID: 20384939
[TBL] [Abstract][Full Text] [Related]
16. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
17. EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.
Okuyucu EE; Guven O; Duman T; Gorur S; Melek IM; Akcin S; Yilmazer S
Neurol Res; 2009 Apr; 31(3):313-5. PubMed ID: 19036180
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary embolism after tadalafil ingestion.
Chen HC; Wang CS; Chuang SH; Wang CY
Pharm World Sci; 2008 Oct; 30(5):610-2. PubMed ID: 18548330
[TBL] [Abstract][Full Text] [Related]
19. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
20. Does therapeutic dose of sildenafil citrate treatment lead to central serous chorioretinopathy in patients with erectile dysfunction?
Damar E; Toklu Y; Tuncel A; Balci M; Aslan Y; Simsek S; Atan A
Am J Mens Health; 2013 Sep; 7(5):439-43. PubMed ID: 23479433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
